Buy Healthscope 

Our Algo Engine triggered a buy signal recently in Healthscope and we continue to see upside potential.

HSO has announced the sale of its Asian Pathology business to TPG Capital Asia for A$279 million. The transaction is expected to be completed by the end of August 2018.

You're not a member!  Trial today

Cash proceeds from the sale will be used to pay down debt and fund new domestic development plans.

The potential for M&A activity, along with the retracement in share price, makes HSO an attractive consideration supported by 3% dividend yield.


Investor Signals Pty Ltd ABN 44 143 555 453 is a Corporate Authorised Representative CAR No. 439411 of Advisor Plus Pty Ltd AFSL 474520
© 2024 Investor Signals

Send our ASX Research to your Inbox

Or start a free thirty day trial for our full service, which includes our ASX Research.